Compass Capital Management Inc. Sells 4,973 Shares of Stryker Corporation $SYK

Compass Capital Management Inc. reduced its holdings in Stryker Corporation (NYSE:SYK) by 3.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 162,263 shares of the medical technology company’s stock after selling 4,973 shares during the quarter. Stryker accounts for about 3.2% of Compass Capital Management Inc.’s investment portfolio, making the stock its 15th largest holding. Compass Capital Management Inc.’s holdings in Stryker were worth $57,031,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Meiji Yasuda America Inc bought a new stake in shares of Stryker in the fourth quarter worth about $3,590,000. Nuveen LLC grew its holdings in shares of Stryker by 2.9% during the fourth quarter. Nuveen LLC now owns 1,567,440 shares of the medical technology company’s stock worth $550,908,000 after buying an additional 44,878 shares in the last quarter. Xponance LLC grew its holdings in shares of Stryker by 5.4% during the fourth quarter. Xponance LLC now owns 63,177 shares of the medical technology company’s stock worth $22,205,000 after buying an additional 3,251 shares in the last quarter. Parnassus Investments LLC grew its holdings in shares of Stryker by 23.1% during the fourth quarter. Parnassus Investments LLC now owns 1,947,575 shares of the medical technology company’s stock worth $684,514,000 after buying an additional 366,059 shares in the last quarter. Finally, Canopy Partners LLC grew its holdings in shares of Stryker by 10.9% during the fourth quarter. Canopy Partners LLC now owns 1,816 shares of the medical technology company’s stock worth $638,000 after buying an additional 179 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last three months. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SYK shares. UBS Group decreased their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Citigroup decreased their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Leerink Partners decreased their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $395.33.

Stryker Stock Down 1.0%

SYK stock opened at $305.82 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average price of $316.75 and a two-hundred day moving average price of $344.20. The company has a market cap of $117.24 billion, a price-to-earnings ratio of 35.40, a P/E/G ratio of 1.95 and a beta of 0.78. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.